Mitsubishi Tanabe
Also known as: Benesis Corporation | Information at Mitsubishi Tanabe Pharma Development America, Inc. | Mitsubihsi Tanabe Pharma Corporation | MITSUBISHI HOLDINGS | MITSUBISHI TANABE | Mitsubishi-Tanabe Pharma | Mitsubishi Tanabe Pharma America Inc. | Mitsubishi Tanabe Pharma Corporation | Mitsubishi Tanabe Pharma Development America, Inc. | Mitsubishi Tanabe Pharma Europe Ltd | Mitsubishi Tanabe Pharma Europe Ltd. | Mitsubishi Tanabe Pharma GmbH | Mitsubishi-Tokyo Pharma | Tai Tien Pharmaceuticals Co., Ltd.
Highest phase reached
Phase 4
First clinical trial
Jan 1, 2001First marketed drug
May 5, 2017First NDA
May 5, 2017Last known activity
Jun 24, 2025
Timeline
1990s
- Jan 1, 1999
Mitsubishi Tanabe— Founded
- Jan 1, 1999
Mitsubishi— Acquired
- Jan 1, 1999
Tanabe— Acquired
2000s
- Jan 1, 2001
Welfide— Acquired
2010s
- Jul 12, 2013
Medicago— Acquired
- May 5, 2017
edaravone— NDA Organization
- May 5, 2017
edaravone— NDA Secondary Org
- Jul 24, 2017
NeuroDerm Ltd.— Acquired
- Nov 22, 2019
riluzole— Marketing Organization
Drugs by trial phase (172 distinct, 336 trials)
Phase 4 (6 own, 10 via acquisition)
Phase 3 (39 own, 32 via acquisition)
Phase 2 (11 own, 33 via acquisition)
Phase 1 (13 own, 18 via acquisition)
Other trials (0 own, 10 via acquisition)
Indications
Approved for
Studied for
- Albuminuria
- Alzheimer Disease
- Amyotrophic Lateral Sclerosis
- Anemia
- Angina, Unstable
- Arthritis
- Arthritis, Psoriatic
- Arthritis, Rheumatoid
- Asthma
- Behcet Syndrome
- Brain Ischemia
- Cerebral Infarction
- Colitis
- Colitis, Ulcerative
- Coronary Artery Disease
- Crohn Disease
- Dermatitis
- Dermatitis, Atopic
- Dermatitis, Exfoliative
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Diabetic Nephropathies
- Diabetic Neuropathies
- Diphtheria
- Dyskinesias
- Dyslipidemias
- Endometriosis
- Fatty Liver
- Gastroesophageal Reflux
- Hepatitis
- Hepatitis A
- Hepatitis C
- Hepatitis C, Chronic
- Hepatitis, Chronic
- Hot Flashes
- Hyperlipidemias
- Hyperlipoproteinemias
- Hyperphosphatemia
- Infarction
- Inflammatory Bowel Diseases
- Intestinal Diseases
- Ischemia
- Kidney Diseases
- Liver Diseases
- Lung Diseases
- Lung Diseases, Obstructive
- Lupus Erythematosus, Systemic
- Meningitis
- Meningitis, Bacterial
- Motor Neuron Disease
- Mucocutaneous Lymph Node Syndrome
- Multiple Sclerosis
- Multiple Sclerosis, Relapsing-Remitting
- Muscle Weakness
- Myasthenia Gravis
- Myocardial Infarction
- Non-alcoholic Fatty Liver Disease
- Osteoarthritis
- Osteoarthritis, Hip
- Osteoarthritis, Knee
- Pain
- Peripheral Arterial Disease
- Peripheral Nervous System Diseases
- Peripheral Vascular Diseases
- Poliomyelitis
- Polyneuropathies
- Polyradiculoneuropathy
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
- Protoporphyria, Erythropoietic
- Psoriasis
- Pulmonary Disease, Chronic Obstructive
- Renal Insufficiency
- Renal Insufficiency, Chronic
- Rhinitis
- Rhinitis, Allergic
- Rhinitis, Allergic, Perennial
- Rhinitis, Allergic, Seasonal
- Schizophrenia
- Scleroderma, Diffuse
- Scleroderma, Systemic
- Sclerosis
- Spinal Cord Injuries
- Stroke
- Tardive Dyskinesia
- Tetanus
- Tetany
- Thrombocytopenia
- Ulcer
- Vascular Diseases
- Whooping Cough
- Wounds and Injuries
Marketed drugs (2)
Subsidiaries (5 direct, 6 total across the full acquisition tree)
Recent trials (50)
- NCT06994286OfficialPhase 1Jun 24, 2025
- NCT06994286Lead sponsorPhase 1Jun 24, 2025
- NCT06943521Lead sponsorPhase 1/Phase 2Apr 18, 2025
- NCT06943521OfficialPhase 1/Phase 2Apr 18, 2025
- NCT06482346OfficialPhase 1Aug 9, 2024
- NCT06482346Lead sponsorPhase 1Aug 9, 2024
- NCT06196905OfficialPhase 1Jun 24, 2024
- NCT06196905Lead sponsorPhase 1Jun 24, 2024
- NCT06144840Study directorPhase 3Dec 11, 2023
- NCT06144840Lead sponsorPhase 3Dec 11, 2023
- NCT05658562Study directorPhase 1/Phase 2Dec 31, 2022
- NCT05658562Lead sponsorPhase 1/Phase 2Dec 31, 2022
- NCT05568615Study directorPhase 3Oct 26, 2022
- NCT05568615Lead sponsorPhase 3Oct 26, 2022
- NCT05396235Lead sponsorPhase 1Aug 3, 2022
Details
- Founded
- Tokyo, JP Jan 1, 1999
- First NDA
- May 5, 2017
- Last known activity
- Jun 24, 2025
Designations held
- Orphan drug
Notes
--- Pre-folding founded info: 2007-10-01 Tokyo JP https://en.wikipedia.org/wiki/Mitsubishi_Tanabe_Pharma ---